Morgan Stanley Acurx Pharmaceuticals, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 46,201 shares of ACXP stock, worth $36,036. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,201
Previous 46,401
0.43%
Holding current value
$36,036
Previous $104,000
16.35%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ACXP
# of Institutions
27Shares Held
1.28MCall Options Held
9.3KPut Options Held
9.7K-
Vanguard Group Inc Valley Forge, PA529KShares$412,8920.0% of portfolio
-
Prospect Financial Services LLC Melville, NY329KShares$256,6790.15% of portfolio
-
Geode Capital Management, LLC Boston, MA147KShares$114,2700.0% of portfolio
-
Lpl Financial LLC Fort Mill, SC44.8KShares$34,9280.0% of portfolio
-
State Street Corp Boston, MA43.5KShares$33,9030.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $9.01M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...